The Role of RAS Modification for Primary and Secondary Stroke Prevention

References

• . Rosamond W, Flegal K, Furie K, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
   PubMed Web of Science ®Google Scholar
• . Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology. 2007;68(19):1583–1587
   PubMed Web of Science ®Google Scholar
• . Goldstein LB, Adams R, Alberts MJ, ; American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council. Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113(24):e873–e923
   PubMed Web of Science ®Google Scholar
• . Schrader J, Kulschewski A, Dendorfer A. Inhibition of the renin-angiotensin system and prevention of stroke. Am J Cardiovasc Drugs. 2007;7(1):25–37
   PubMedGoogle Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . Neal B, MacMahon NB, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;356(9246):1955–1964
   PubMed Web of Science ®Google Scholar
• . PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358(9287):1033–1041
   PubMed Web of Science ®Google Scholar
• . Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006;12(13):1581–1592
   PubMed Web of Science ®Google Scholar
• . Magy L, Vincent F, Faure S, . The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des. 2005;11(25):3275–3291
   PubMedGoogle Scholar
• . Chobanian AV, Bakris GL, Black HR, ; National Heart, Lung, and Blood Institute Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, . Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10(8):803–812
   PubMedGoogle Scholar
• . Li M, Liu K, Michalicek J, . Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest. 2004;114(1):112–120
   PubMed Web of Science ®Google Scholar
• . Matchar DB, McCrory DC, Orlando LA, . Comparative effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. 10. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Contract no. 290-02-0025. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed November 7, 2008
   Google Scholar
• . Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACP evidence-based clinical practice guidelines. Chest. 2006;129( 1 Suppl):169S–173S
   PubMed Web of Science ®Google Scholar
• . Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich). 2002;4(5): 375–380
   PubMedGoogle Scholar
• . Azizi M, Ménard J. Combined blockade of the rennin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109(21):2492–2499
   PubMed Web of Science ®Google Scholar
• . Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother. 2007;41(3):456–464
   PubMedGoogle Scholar
• . Zhou Y, Yu F, Ene AR, Catanzar DF. Telmisartan ramipril combination therapy reduces strokes and improves cardiac and renal protection in stroke-prone spontaneously hypertensive rats. J Am Soc Hypertens. 2007;1:423–432
   PubMedGoogle Scholar
• . Takada J, Ibayashi S, Ooboshi H, . Valsartan improves the lower limit of cerebral autoregulation in rats. Hypertens Res. 2006;29(8):621–626
   PubMedGoogle Scholar
• . Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004;35(7):1726–1731
   PubMed Web of Science ®Google Scholar
• . Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke. 2002;33(9):2297–2303
   PubMed Web of Science ®Google Scholar
• . Chrysant SG. Possible pathophysiological mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens. 2005;19(12):923–931
   PubMedGoogle Scholar
• . Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(18): 145–153
   PubMedGoogle Scholar
• . ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997
   PubMed Web of Science ®Google Scholar
• . Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328(7441):495–500
   PubMedGoogle Scholar
• . Beckett NS, Peters R, Fletcher AE ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898
   PubMed Web of Science ®Google Scholar
• . Dahlöf B, Sever PS, Poulter NR, ; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering ARM (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906
   PubMed Web of Science ®Google Scholar
• . Jamerson KA; ACCOMPLISH Investigators. Avoiding cardiovascular events in combination therapy in patients livin with systolic hypertension. Presented at: American College of Cardiology 57th Annual Scientific Sessions; Chicago, IL: March 29-April 1, 2008
   Google Scholar
• . Dahlöf B, Devereux RB, Kjeldsen SE, ; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Kjeldsen SE, Dahlöf B, Devereux RB, ; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288(12):1491–1498
   PubMed Web of Science ®Google Scholar
• . Devereux RB, Dahlöf B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin. 2007;23(2):443–157
   PubMed Web of Science ®Google Scholar
• . Lithell H, Hansson L, Skoog I, ; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE); principal results of a randomized, double-blind intervention trial. J Hypertens. 2003;21(5):875–886
   PubMed Web of Science ®Google Scholar
• . Papademetriou V, Farsang C, Elmfeldt D, ; Study on Cognition and Prognosis in the Elderly Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–1180
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M, ; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Julius S, Weber MA, Kjeldsen SE, . The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):385–391
   PubMed Web of Science ®Google Scholar
• . Mochizuki S, Dahlöf B, Shimizu M, ; Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(3571): 1431–1439
   PubMedGoogle Scholar
• . Staessen JA, Richart T. Sum and substance in the Jikei Heart Study. Lancet. 2007;369(9571):1407–1408
   PubMedGoogle Scholar
• . Yusuf S, Teo K, Anderson C, ; Telmisartan Randomised Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–1183
   PubMed Web of Science ®Google Scholar
• . Ripley TL, Harrison D. The power to TRANSCEND. Lancet. 2008;372(9644):1128–1130
   PubMedGoogle Scholar
• . Yusuf S, Teo KK, Pogue J, ; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Schrader J, Lüders S, Kulschewski A, ; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34(7):1699–1703
   PubMed Web of Science ®Google Scholar
• . Schrader J, Lüders S, Kulschewski A, ; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218–1226
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Diener HC, Sacco RL, ; PRoFESS Study Group. Telmisartan to prevent recurrent strokes and cardiac events. N Engl J Med. 2008;359(12):1225–1237
   PubMed Web of Science ®Google Scholar